A Clinical Study on the Safety and Efficacy of Allogeneic CAR T Cells Targeting BCMA in the Treatment of Adult r/r Multiple Myeloma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with r/r multiple myeloma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Expected survival of at least 3 months;
• Subjects should have measurable disease that meets the IMWG 2016 criteria;
• Previously received at least two lines of prior anti-myeloma therapy ；
• Relapse , failure to achieve at least a minimal response, or disease progression after the last treatment ；
• BCMA positive；
• ECOG score 0-1；
• No severe impairment or suppression of liver, kidney, coagulation, bone marrow, or lung function.
Locations
Other Locations
China
Shanghi Tongji Hospital (Tongji Hospital of Tongji University)
RECRUITING
Shanghai
Contact Information
Primary
Ping Li, phD
lilyforever76@126.com
13564181131
Time Frame
Start Date: 2025-04-10
Estimated Completion Date: 2028-04-18
Participants
Target number of participants: 6
Treatments
Experimental: Treatment group
5.0-10×10\^6cells/kg
Related Therapeutic Areas
Sponsors
Leads: Bioray Laboratories
Collaborators: Shanghai Tongji Hospital (Tongji Hospital of Tongji University)